Leckman Patricia sold $127K of ILMN

Leckman Patricia (SVP, Chief People Officer) sold 783 shares of ILLUMINA, INC. (ILMN) at an average of $162.59 ($161.79–$167.88, $0.13M total) across 5 trades on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leckman Patricia
Published Jun 9, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new fundamentals, guidance, litigation, or operational changes.

02

Market read

Primarily a sentiment/positioning datapoint; likely low impact on valuation absent corroborating fundamental news.

03

What to watch

Because it’s explicitly a pre-arranged 10b5-1 plan, the sale timing is less informative than discretionary selling.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-09 (covers sale dated 2026-06-05).

Background

The article is a primary-source SEC Form 4 insider transaction disclosure (open-market sale) for Illumina.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina insider Form 4 shows SVP Chief People Officer Patricia Leckman sold 783 shares for ~$127.3K under a 10b5-1 plan on 2026-06-05.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with modest dollar value relative to typical large-cap trading.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Traders sometimes treat clustered insider sales as a sentiment check; if broader insider selling is occurring, this could reinforce a cautious tape.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Patricia Leckman

    SVP, Chief People Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.